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Abstract: Background: Parenteral nutrition is often a mandatory therapeutic strategy for cases
of septicemia. Likewise, therapeutic application of anti-oxidants, anti-inflammatory therapy, and
endotoxin lowering, by removal or inactivation, might be beneficial to ameliorate the systemic
inflammatory response during the acute phases of critical illness. Concerning anti-inflammatory
properties in this setting, omega-3 fatty acids of marine origin have been frequently described.
This study investigated the anti-inflammatory and LPS-inactivating properties of krill oil
(KO)-in-water emulsion in human macrophages in vitro. Materials and Methods: Differentiated
THP-1 macrophages were activated using specific ultrapure-LPS that binds only on the toll-like
receptor 4 (TLR4) in order to determine the inhibitory properties of the KO emulsion on the
LPS-binding capacity, and the subsequent release of TNF-α. Results: KO emulsion inhibited the
macrophage binding of LPS to the TLR4 by 50% (at 12.5 µg/mL) and 75% (at 25 µg/mL), whereas,
at 50 µg/mL, completely abolished the LPS binding. Moreover, KO (12.5 µg/mL, 25 µg/mL,
or 50 µg/mL) also inhibited (30%, 40%, or 75%, respectively) the TNF-α release after activation
with 0.01 µg/mL LPS in comparison with LPS treatment alone. Conclusion: KO emulsion influences
the LPS-induced pro-inflammatory activation of macrophages, possibly due to inactivation of the
LPS binding capacity.
Keywords: krill oil-in-water emulsion; omega-3 fatty acids; phospholipids; LPS; cytokines;
septic shock
1. Introduction
Sepsis and septic shock due to Gram-negative pathogens are responsible for significant morbidity
and mortality in human populations [1]. LPS binding to phagocytic cells stimulates the synthesis and
release of cytokines, such as TNF-α, IL-1β, and IL-6 [2]. Cytokine secretion is an important component
of host defense, but when overstimulation occurs, excessive cytokine secretion may lead to the systemic
signs and symptoms of sepsis [3]. Exogenous or endogenous stimulation of biological factors that
modulate the extent of binding of LPS to monocytes and macrophages may play a pivotal role in
determining the outcome of endotoxin exposure [1]. In this context, serum factors that bind LPS may
prevent macrophage activation [4]. In vitro and in vivo, HDL binds LPS and neutralizes it and the
LPS-induced cytokine response is attenuated [5,6]. However, the phospholipid (PL) content, rather
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than the cholesterol content, correlates with the effectiveness of LPS neutralization [7]. Additionally,
circulating levels of HDL are reduced in sepsis/septic shock, and this reduction is positively correlated
with the severity of the illness [8], and decreased LDL levels (≤70 mg/dL) were associated with
increased risks of sepsis [9]. In an optimal way, the substance used to neutralize the endotoxin effect
during sepsis should be anti-oxidative, anti-inflammatory, and with endotoxin-binding capacity. In this
context, omega-3 fatty acids (n-3 fatty acids) decrease the production of inflammatory eicosanoids,
cytokines, reactive oxygen species (ROS) and adhesion molecules [10]. The key link between PUFAs
and inflammation is that eicosanoids, which are among the primary mediators and regulators of
inflammation during acute metabolic stress, are generated from 20-carbon PUFAs [10]. The three
types of omega-3 fatty acids involved in human physiology are α-eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA), both of which are usually found in marine fish oils and linolenic acid
(ALA), commonly found in plant oils. With respect to the precursor fatty acid ALA, in human it has
poor bioconversion to the essential omega-3 fatty acids EPA and DHA and, therefore, it is an unreliable
source for these bioactive fatty acids [11]. In this context, fish oil dietary supplements play a role of
increasing the strategic importance in meeting daily requirements of essential nutrients [12].
Applications of intravenous lipid emulsions containing fish oil reduce the length of stay in
hospital [13], as well as antibiotic use and mortality [14]. Moreover, fish oil with parenteral nutrition
provided to septic intensive care patients increases plasma EPA, modifies inflammatory cytokine,
improves gas exchange [15], and may exert profound influence on the status of immunocompetence
and inflammation [16,17] The anti-inflammatory properties of marine omega-3 fatty acids have already
been described [18,19]. In addition to triglycerides, marine n-3 fatty acids are also available in other
forms, such as in crude krill oil (KO), which provides EPA and DHA, mainly in the form of PLs, and
as ethyl esters of pharmaceutical grade, highly-concentrated preparations [18]. In this context, most
recently, KO, which contains a significant portion of its n-3 LC-PUFA in PLs, is also increasingly found
on the market, and is promoted as being of “higher efficacy” [12,20]. Additionally, most recently a new
product category, derived from Antarctic krill (Euphausia superba Dana), has been brought onto the
omega-3 market, characterized by a greater ease of absorption due to higher PL content [12,20].
KO comes from sustainable fisheries and is nearly at the beginning of a food chain, compared with
fish sources that are more affected by environmental pollutants [12,20]. In addition, a higher fraction
of omega-3 LC-PUFA is associated with PLs in KO, compared to triacylglycerol in fish oils, and this
property may improve gastrointestinal absorption and bioavailability of omega-3 LC-PUFA [21]. KO
contains PUFAs, including the bioactive EPA and DHA, (up to 35% w/w of the fatty acids profile),
with up to 95% w/w PLs and up to 45% triglycerides [22]. According to these characteristics, we
hypothesize that an injectable KO emulsion might in vitro exert anti-inflammatory properties from
the presence of omega-3 fatty acids, and also bind endotoxin, thereby inhibiting LPS mediated effects,
i.e., LPS is less able to stimulate and activate macrophages to release pro-inflammatory cytokines.
2. Results
2.1. Effect of KO Emulsion or LPS on the Viability of Differentiated Human THP-1 Macrophages
As shown in Figure 1A, we found that, after 24 h, treatment with 5–250 µg/mL KO did not
display any cytotoxicity. Glycerol used as the vehicle was not cytotoxic (Figure 1A). Incubation of
differentiated human THP-1 macrophages for 4 h with LPS did not show cytotoxicity (Figure 1B).
2.2. Effect of KO Emulsion on the LPS Binding
We used two binding assays to evaluate the interaction of LPS with macrophage-TLR4 and the
inhibitory effect of KO. As shown in Figure 2, macrophages incubated 24 h with 1 µg or 5 µg/mL
LPS-EB-biotin displays positive binding, detected by fluorescence (Figure 2), compared with controls
without LPS.
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Figure 1. (A) Effects of 24 h treatment with KO emulsion or the glycerol vehicle (numbers in brackets 
indicate the volume of glycerol used in the corresponding KO concentration), on the viability of THP‐
1 macrophages. Values (in % viability of cells without treatment (control = 100%)) are given as the 
mean + SEM; ANOVA test, significance vs. negative control, ** p ≤ 0.01, *** p ≤ 0.001; n = 7 independent 
experiments; and  (B)  the effects of 4 h  treatment with ultrapure LPS‐EB‐biotin on  the viability of 
differentiated human THP‐1 macrophages. Values (in % viability of cells without treatment (control 
= 100%)) are given as the mean + SEM; n = 4 independent experiments. 
 
Figure 2. Effect of the KO emulsion on the LPS binding by differentiated human THP‐1 macrophages. 
Photographs  of  the  inhibitory  effect  of KO  on  the  binding  of ultrapure LPS‐EB‐biotin  after  24 h 
incubation, was detected with streptavidin‐Cy3‐conjugated as fluorochrome. White arrows: nuclei. 
Magnification: 200×. 
Figure 1. (A) Effects of 24 h treatment with KO emulsion or the glycerol vehicle (numbers in brackets
indicate the volume of glycerol used in the corresponding KO concentration), on the viability of
THP-1 macrophages. Values (in % viability of cells without treatment (control = 100%)) are given
as the mean + SEM; ANOVA test, significance vs. negative control, ** p ≤ 0.01, *** p ≤ 0.001; n = 7
independent experiments; and (B) the effects of 4 h treatment with ultrapure LPS-EB-biotin on the
viability of differentiated human THP-1 macrophages. Values (in % viability of cells without treatment
(control = 100%)) are given as the mean + SEM; n = 4 independent experiments.
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LPS (1 µg/mL) pre-incubated with KO (100 µg/mL) inhibited the binding, but not when using
LPS at a concentration of 5 µg/mL (Figure 2). The LPS binding was increased at 0.1 µg/mL (6.5%),
1 µg/mL (20.3%, p ≤ 0.05), and 5 µg/mL (100%, p ≤ 0.05) when compared with the negative control
(Figure 3).
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Figure 3. Effect of the KO emulsion on the LPS binding on macrophage-TLR4. Ultrapure LPS-EB-biotin
binding assay was performed by using PMA-differentiated THP-1 macrophages after 3 h incubation,
including streptavidin-HRP-OPD system for detection and colorimetric quantification. Values
(binding relative to negative control (value = 1) without LPS-EB-biotin) are given as the mean + SEM;
ANOVA test, significance vs. negative control without LPS, * p ≤ 0.05; n = 4 independent experiments.
After co-incubation of 0.1 µg/ L LPS-EB with KO, the macrophages were treated for 3 h with
different concentrations of LPS + KO: at 12.5 µg/mL LPS + KO, LPS-binding decreased by 50%
(not significant); at 25 µg/mL LPS + KO LPS binding significantly decreased by 75% (p ≤ 0.05) and,
at 50 µg/mL LPS + KO, it was abolished (p ≤ 0.01), as shown in Figure 4.
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Figure 4. Ultrapure LPS-EB-biotin binding assay on macrophage-TLR4. LPS-EB-biotin (0.1 µg/mL) was
co-incubated overnight with different concentrations of KO emulsion or LPS antagonist (LPS-RS AN),
added to differentiated THP-1 macrophages (3 h). LPS binding was spectrophotometrically quantified
using streptavidin-HRP-OPD system. Values (in % binding relative to positive control (100% binding)
with LPS-EB-biotin) are given as the mean + SEM; ANOVA test, significance vs. positive control
(=LPS-EB-Biotin), * p ≤ 0.05, ** p ≤ 0.01; n = 6 independent experiments.
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As the LPS-binding control, 25 µg/mL nLDL showed a similar effect as KO at 12.5 µg/mL,
however, this was not significant. LPS-RS-AN antagonist significantly (p ≤ 0.01) prevented the binding
of LPS-biotin and, thus, mimicked the effect of KO (Figure 4). A total and significant inhibition of
the binding was obtained when 1 µg/mL LPS-EB was co-incubated with 6.25, 12.5 µg/mL (p ≤ 0.01),
25 µg/mL (p ≤ 0.01), or 50 µg/mL (p ≤ 0.001) KO when compared with the control. Furthermore, LDL
showed a similar inhibition pattern as KO. Additionally, the LPS-RS antagonist completely inhibited
the LPS binding on the TLR4 (Figure 5). Moreover, we have performed this experiment using 5 µg/mL
LPS-EB-biotin, however, without a statistically significant difference between LPS/KO co-incubation
and LPS alone (data not shown).
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Figure 5. Ultrapure LPS-EB-biotin binding assay on macrophage-TLR4. LPS-EB-biotin (1 µg/mL)
was co-incubated overnight together with different concentrations of KO emulsion or 100 µg/mL
LPS antagonist (LPS-RS AN) added to differentiated human THP-1 macrophages (3 h). LPS binding
was spectrophotometrically quantified using streptavidin-HRP-OPD system. Values (in % binding
relative to positive control (100% binding) with LPS-EB-biotin) are given as the mean + SEM; ANOVA
test, significance vs. positive control (=LPS-EB-Biotin), * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001; n = 6
independent experiments using four wells per treatment and experiment.
2.3. Effect of KO Emulsion on TNF-α Release of Differentiated Human THP-1 Macrophages Stimulated
with LPS-EB
The TNF-α releas in cell supern tants of ifferentiated uman THP-1 macrophages treated with
LPS-EB (pre-i cubated with KO) was markedly reduced wh n 0.01 µg/mL r 0.1 µg/mL PS was
used. A significant inhibition of the TNF-α release was obtained after incubation of 0.01 µg/mL LPS
with 12.5 µg/mL (−30%, p ≤ 0.01), 25 µg/mL (−40%, p ≤ 0.001) or 50 µg/mL (−75%, p ≤ 0.001) KO
in comparison with the control LPS (Figure 6A).
Treatment with 0.1 µg/mL LPS pre-incubated with 25 µg/mL or 50 µg/mL KO showed a 50%
(p ≤ 0.05) or 60% (p ≤ 0.01) inhibition in comparison with control LPS (Figure 6B). Treatment with KO
alone had no effect on the TNF-α production (Figure 6B). Incubation with antagonist LPS-RS abolished
the TNF-α release (Figure 6B).
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patients [26]. Sepsis‐associated organ failure and death result from an overwhelming inflammatory 
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ROS levels are controlled by endogenous anti‐oxidant systems, sepsis induces an imbalance between 
pro‐ and antioxidant systems, which leads to oxidative stress [29]. Moreover, long‐chain n‐3 PUFAs 
decrease the production of inflammatory mediators (eicosanoids, cytokines, and ROS) [22,30]. Once 
incorporated into cell membranes, a key step to exert cytoprotection, n‐3‐FAs dramatically modulate 
the  body’s  response  to  inflammation,  oxidative  stress,  ischemia,  and  immune  function  through 
several  downstream  bioactive  mediators,  (e.g.,  cytokines,  prostaglandins,  thromboxanes, 
leukotrienes,  resolvins, protectins,  etc.)  [22]. The  combination of  “cytoprotective  excipients”  [31], 
together with nutritional, anti‐oxidant, and anti‐inflammatory properties, make the omega‐3 therapy 
a successful candidate for the management of sepsis in patients under intensive care. By using EPA 
Figure 6. Analyses (by ELISA) of the inhibitory effect of KO emulsion on the TNF-α release by LPS-EB
differentiated human THP-1 macrophages. (A) LPS-EB 0.01 µg/mL, or (B) 0.1 µg/mL was co-incubated
overnight together with different concentrations of KO or 10 µg/mL LPS antagonist (LPS-RS-AN) and
afterwards for 3 h with the differentiated THP-1 macrophages. Values (in %TNF-α release relative to
positive (LPS-EB) control (=100% release)) are given as the mean + SEM; ANOVA test, significance vs.
positive control (=LPS-EB), * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001; n = 3–5 independent experiments.
3. Discussion
Sepsis has been defined as a systemic i ti in patients with infection, characterized
by low rates of survi al [23]. Bacterial endot xe ia is c sidered one of the major causes of sepsis,
resulting from the release of LPS by icroorganis s, e.g., within the colon, that translocate across
a compromised intestinal wall [17,24]. In this context, we performed in vitro experiments to test the
efficacy of a KO emulsion against endotoxin-triggered pro-inflammatory effects.
Death rates in patients caused by sepsis reach about 30%–80% [25], especially in oncologic
patients [26]. Sepsis-associated organ failure and death result from an overwhelming inflammatory
immune response that culminates in a generalized autodestructive process [27] and development of
multi-organ dysfunction syndrome, or MODS [28]. Under normal physiological conditions, in which
ROS levels are controlled by endogenous anti-oxidant systems, sepsis induces an imbalance between
pro- and antioxidant systems, which leads to oxidative stress [29]. Moreover, long-chain n-3 PUFAs
decrease the production of inflammatory mediators (eicosanoids, cytokines, and ROS) [22,30]. Once
incorporated into cell membranes, a key step to exert cytoprotection, n-3-FAs dramatically modulate
the body’s respons to inflammation, oxidative stress, ischemia, and immune function through
several dow stream bioactive mediators, (e.g., cytokines, prostaglandins, thromboxanes, leukotrienes,
resolvins, pro ectins, etc.) [22]. The combin tion of “cytoprotective xcipients” [31], together with
nutritional, anti-oxi nt, and anti-infla matory roperties, make the omega-3 th rapy a successful
candidate for the management of sepsis in patients under intensive care. By using EPA or fish oil,
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inhibition of endotoxin-induced TNF-α production by monocytes [32], may exert effects on both,
the generation of inflammatory mediators, and on the resolution of inflammatory processes [15].
These observations suggest direct effects of long-chain n-3 PUFA on inflammatory gene expression
via inhibition of activation of the transcription factor NF-κB [33]. Several studies in healthy human
volunteers involving supplementation of the diet with fish oil have demonstrated decreased production
of TNF-α, IL-1β, and IL-6 after endotoxin-stimulation of monocytes or mononuclear cells [34,35].
The benefits of fish oil in animal models of experimental endotoxemia have been clearly demonstrated
when dietary fish oil or fish oil infused intravenously enhances the survival of guinea pigs after
intraperitoneal endotoxin injection [36]. In this context, strategies to attenuate the immune response
and prevent organ failure could help patients with sepsis or septic shock. Given that ultrapure LPS-EB
specifically binds to TLR4 and the LPS antagonist LPS-RS, leading to an almost complete suppression
of the TNF-α release, confirms the specific binding of LPS-EB to TLR4. The same effect observed with
KO, can be explained by an inactivation of LPS during the co-incubation with KO or an inhibition
of the binding to TLR4. Nevertheless, the present study clearly demonstrates that KO inhibited the
production of TNF-α after stimulation with LPS. Available data have confirmed an effective reduction
in the LPS level in the patients’ blood after this procedure [37], and could effectively eliminate a wide
range of the factors as LPS, cytokines, etc., from peripheral blood.
Our findings suggest that KO has properties to inactivate and bind LPS, leading to the inhibition
of activation of macrophages. In this context, we found a reduction of LPS binding capacity on
differentiated human THP-1 macrophages after 3 h treatment with LPS that has been co-incubated
(24 h) with 100 µg/mL KO (Figure 2), by reduction of the fluorescence intensity at a concentration of
1 µg/mL LPS (Figure 2). These data support studies showing less LPS internalization into murine
macrophages after 24 h treatment, when LPS was pre-exposed to high-density lipoprotein (HDL) [4].
In agreement with these studies, we used human LDL as binding control and we found that LDL
reduced the binding of LPS on macrophages (Figures 4 and 5). Moreover, KO significantly reduced
the LPS-binding on macrophages over a range of LPS concentrations when both had been previously
co-incubated and, afterwards, were applied to the macrophages. Human serum or LDL inactivate
endotoxins and inhibit the IL-1β release in LPS-activated monocytes [38]. Consequently, this observed
KO characteristic may be a sign of a possible LPS adsorption, inactivation, or hiding of the binding
sites. Using the LPS antagonist Rhodobacter sphaeroides, which binds to the TLR4 but does not induce
TLR4 signaling, we can confirm the specificity of the activation (Figures 4 and 5). After co-incubation
(24 h) of LPS and KO (12.5, 25 or 50 µg/mL), LPS lost its pro-inflammatory capacity and inhibited the
TNF-α release. KO alone or LPS antagonist did not affect the TNF-α production, and confirmed that
KO has beneficial, and not detrimental, effects. Therefore, our results impressively indicate that KO
can efficiently prevent macrophages from being activated by LPS, including suppression of negative
consequences. like the release of pro-inflammatory cytokines, such as TNF-α.
The effects we have observed with a KO emulsion are likely the result of two main mechanisms
of action. First, the phopsholipids present in KO bind and neutralize LPS endotoxin. This effect
has been shown previously in a study of normal human volunteers receiving an intravenous
dose of Escherichia coli endotoxin during a 6-h PL infusion, and attenuation of the clinical and
laboratory responses were directly related to PL levels in the bloodstream [39]. However, when
this formulation was tested in the critical care setting in patients with severe Gram-negative sepsis, the
high dose arm (1350 mg/kg by continuous infusion) had to be stopped because of the increased
incidence of life-threatening significant adverse events and obvious futilty to show a survival
advantage [40]. The PL emulsion used in this investigation consisted of 92.5% soy-based, PL, and 7.5%
soy triglycerides. Although this formulation contained PLs capable of binding endotoxin, the dosing
was probably excessive. Additionally, the fatty acid profile of soybean oil-derived triacylglycerols and
phosphoglycerides mainly contain pro-inflammatory omega-6 fatty acids (i.e., linoleic acid). In contrast,
the KO-based PL emulsion in the present study contained both the necessary PL to bind the endotoxin,
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plus the anti-inflammatory omega-3 fatty acids to modulate eicosanoid metabolism, and they clearly
exhibit positive synergistic effects.
Finally, the KO emulsion used in this study was a crude formulation made from an unrefined
natural source that is widely found in oral supplements and, thus, would be unsuitable for
intravenous administration. Therefore, our study provided an indication of a proof-of-concept with
this phospholipid-omega-3 combination in a cell culture model. We clearly recognize that for such a
product to be a potentially viable injectable emulsion in the clinical setting, the crude KO would need
to undergo refinement steps (similar to that applied to fish oil) [41] to concentrate the PL in amounts
and levels of purity similar to currently available and widely used egg PL which, for example, contain
at least 80% phosphatides (versus ~40%, and about equal amounts of triglycerides). In addition,
since the triglycerides present in crude KO are essentially devoid of omega-3 fatty acids, the ideal
injectable product would also include fish oil triglcyerides enriched with omega-3 fatty acids for
maximal therapeutic efficacy.
We conclude that KO emulsion inhibits the LPS-binding on macrophage-TLR4 and, thus, the
TNF-α release induced by LPS in vitro. The addition of omega-3 fatty acids potentiates the therapeutic
actions by reducing the intensity of the systemic inflammatory response. These properties may be
beneficial for patients under intensive care with septicemia.
4. Materials and Methods
4.1. Krill Oil-In-Water Emulsion
Three separate batches of a 5% KO-in-water emulsion were aseptically prepared in the laboratory
and sterilized prior to use. This was done to be sure the emulsions could be successfully made using
a crude source of KO, since a pharmaceutical-quality grade, suitable for parenteral administration,
does not exist. The mean droplet size of all the emulsions was approximately 190 nm and, thus, they
were considered pharmaceutically equivalent. The composition of the final emulsions are shown in
Table 1.
Table 1. Krill oil-in-water emulsion.
Ingredient Amount/1000 mL
Glycerol 25.0 g
Krill Oil * 50.0 g
Sterile Water for Injection 1000 mL
pH 6.89 ± 0.06
* Virgin Krill Oil, LLC, Braintree, MA, USA, Lot #1107091, Key Ingredient Totals (w/w): n-3-FAs = 26%; PLs = 41.2%.
4.2. Cells and Culture Conditions
The in vitro experiments were performed using the THP-1 (human acute monocytic leukemia)
cell line (DSMZ GmbH, Braunschweig, Germany), cultured in 90% RPMI-1640 (PAA GmbH, Cölbe,
Germany), 10% FBS (PAA GmbH); 100 U/mL penicillin; and 0.1 mg/mL streptomycin (PAA GmbH).
All experiments were carried out in medium with 10% FBS.
4.3. Determination of LPS and KO Emulsion Cytotoxicity
THP-1 (5 × 104) cells were seeded in 96-well plates (BD Falcon™, Becton Dickinson GmbH,
Heidelberg, Germany). After differentiation with 0.1 µg/mL phorbol-12-myristate-13-acetate (PMA)
Sigma-Aldrich, St. Louis, MO, USA), the medium was changed and the macrophages treated with
0.05 µg/mL-10 µg/mL ultrapure biotinylated lipopolysaccharide (LPS-EB) from E. coli O111:B4
(Cayla-InvivoGen Europe, Toulouse, France), which is recognized only by toll-like receptor-4 (TLR4);
KO 5 µg/mL to 250 µg/mL, or glycerol. After 24 h KO or 4 h LPS treatment, viability was assessed
using PrestoBlue™ reagent (Invitrogen-Life Technologies GmbH, Darmstadt, Germany). After 1 h the
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optical density (OD) was measured at 570 nm/600 nm with a SUNRISE ELISA-reader (Tecan Salzburg,
Austria). Results are expressed as the % of viability/survival (OD570 nm/600 nm of samples ×
100/OD570 nm/600 nm of control without substances).
4.4. Determination of the LPS Binding on Differentiated THP-1 Macrophages, Effect of the Treatment with KO
Emulsion, Detected by Fluorescence Microscopy
THP-1 (5 × 104) cells were seeded in 100 µL medium/well in 96-well plates (BD Falcon™).
After eight days of differentiation into macrophages using 0.1 µg/mL PMA, the medium was changed
and the macrophages were treated with 1 µg/mL or 5 µg/mL ultrapure LPS-EB-biotin alone or
with KO. After 3 h the cells were fixed with 1% paraformaldehyde (PFA/PBS) for 20 min and
incubated afterwards with streptavidin-Cy3 (Dianova, Hamburg, Germany). Digitalized images
were obtained using an inverted microscope Eclipse-TS100 (Nikon GmbH, Düsseldorf, Germany) and
an AxioCamMRc/AxioVision digital imaging system (Carl Zeiss GmbH, Jena, Germany).
4.5. Determination of the LPS Binding on Differentiated THP-1 Macrophages Detected by Spectrophotometry
THP-1 (5 × 104) cells were seeded as described above and treated with 0.1 µg/mL,
1 µg/mL, or 5 µg/mL ultrapure LPS-EB-biotin. After 3 h the macrophages were fixed with
1% PFA/PBS for 20 min, then incubated with streptavidin-biotinylated horseradish peroxidase
(HRP-streptavidin-biotin) complex Amersham (GE Healthcare Europe GmbH, Freiburg, Germany).
Subsequently, the macrophages were incubated with 50 µL peroxidase substrate Sigma Fast™ (OPD)
(Sigma-Aldrich, St. Louis, MO, USA) for 30 min at RT. The reaction was stopped with 25 µL 3N
HCl, and the absorbance was measured at 490 nm/655 nm. Afterwards, the cells were stained with
crystal violet solution (0.04% paraformaldehyde crystal violet in 4% (v/v)). The OPD absorbance was
normalized against the crystal violet absorbance measured at 595 nm/660 nm.
4.6. Inhibitory Effects of the KO Emulsion on the LPS Binding Capacity
PMA-differentiated THP-1 macrophages were treated for 3 h with the LPS-EB-biotin and KO
mixture (both previously incubated together at 4 ◦C overnight), afterwards the cells were fixed
with 1% PFA-PBS for 20 min, washed with PBS, incubated with streptavidin-biotin-complex-HRP
(Amersham, GE Healthcare), afterwards with OPD and measured as described above. The positive
control was performed by incubation of macrophages with ultrapure LPS-EB-biotin alone and the
negative controls incubated only with medium or with KO. In humans, low-density lipoproteins (LDLs)
may bind LPS and inactivate it; we used native LDL (nLDL, HoelzelDiagnostika GmbH, Cologne,
Germany) as a control to compare the adsorption properties of KO [38]. The antagonist LPS from
Rhodobactersphaeroides (LPS-RS) was used as control of the TLR4 specific binding by competitive
inhibition at 100-fold excess of the agonist LPS-EB.
4.7. Effects of the KO Emulsion on TNF-α Release
The release of TNF-α was determined using ELISA. Therefore, 5 × 105 THP-1 cells were
seeded in 24-well plates (BD Falcon™). After five days of PMA-induced differentiation (0.1 µg/mL),
the macrophages were treated 3 h with LPS-EB and KO (previously incubated as described). After the
treatment, the culture medium was harvested and centrifuged at 500× g (5 min). The cells were
homogenized in RIPA buffer (Cell Signaling Technology, Inc., Danvers, MA, USA) for protein
quantification using the bicinchoninic acid assay (Thermo Fisher Scientific, Bonn, Germany). Human
TNF-α was determined in the supernatant using the DuoSet-ELISA kit (R&D Systems Europe,
Ltd., Abingdon, UK) according to the manufacturer’s instructions; 96-well NUNC MaxiSorp™
(Thermo Fisher Scientific) were used. The amount of TNF-α was normalized with the protein content.
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4.8. Statistical Analyses
The SigmaPlot®-12 software (Systat Software GmbH, Erkrath, Germany) was used to carry out
statistical analyses by one-way analysis of variance test (ANOVA) using Dunnett’s method appropriate
for multiple comparisons versus the control group. Data are shown as mean + SEM.
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